Turnstone teams up with Moffitt to race TIL cell therapies into the clinic
Turnstone Biologics is charging ahead with its expansion into tumor-infiltrating lymphocytes (TILs), striking a deal with the Moffitt Cancer Center to complement the capabilities it picked up in its takeover of Myst Therapeutics at the start of the year.